Skip to main content
Eveline Wu, MD, Allergy & Immunology, Chapel Hill, NC

EvelineWuMDMSCR

Allergy & Immunology • Chapel Hill, NC

Pediatric Asthma & Allergic Conditions, Clinical & Laboratory Immunology

Associate Professor of Pediatrics, Pediatric Rheumatology, Allergy and Immunology

Join to view full profile

Dr. Wu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wu's full profile

Already have an account?

  • Office

    101 Manning Dr
    Chapel Hill, NC 27514
    Phone+1 919-962-5136
    Fax+1 919-962-4421

Education & Training

  • UNC Gillings School of Global Public Health
    UNC Gillings School of Global Public HealthMSCR, Clinical Research, 2013 - 2016
  • Duke University Hospital
    Duke University HospitalFellowship, Allergy and Immunology, 2008 - 2013
  • Duke University Hospital
    Duke University HospitalFellowship, Pediatric Rheumatology, 2008 - 2013
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Pediatrics, 2005 - 2008
  • Mercer University School of Medicine
    Mercer University School of MedicineClass of 2005

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2008 - 2025
  • American Board of Allergy and Immunology Allergy & Immunology
  • American Board of Pediatrics Pediatric Rheumatology

Publications & Presentations

PubMed

Journal Articles

  • Review and Feature Article Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review  
    Ronald J Falk, Eveline Y Wu, Michelle L Hernandez, ScienceDirect
  • Management of vasculitic glomerulonephritis  
    Wu EY, Pendergraft III WF, Nachman PH, Curr Treatm Opt Rheumatol, 6/2016

Other

Press Mentions

  • Pharming Announces US FDA Approval of Joenja® (Leniolisib) as the First and Only Treatment Indicated for APDS
    Pharming Announces US FDA Approval of Joenja® (Leniolisib) as the First and Only Treatment Indicated for APDSMarch 24th, 2023
  • The 2020 ACR Review Course: Key Issues Rheumatologists Face
    The 2020 ACR Review Course: Key Issues Rheumatologists FaceDecember 17th, 2020
  • Researchers Seek ANCA-Associated Vasculitis Subtype Markers
    Researchers Seek ANCA-Associated Vasculitis Subtype MarkersOctober 19th, 2020

Professional Memberships

Dr. Eveline Wu, Dr. Eveline Wu, MD, Dr. E Wu